News and Press Releases 2008

RSS Feeds

• November 24, 2008
  Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients with Gout
• October 6, 2008
  Takeda’s Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
• September 23, 2008
  Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
• August 13, 2008
  More than 300 Takeda Employees Refurbish Waukegan's Thomas Jefferson Middle School
• July 1, 2008
  Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. Merge
• June 7, 2008
  Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
• May 27, 2008
  AMITIZA® (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
• May 18, 2008
  New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
• May 17, 2008
  Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
• May 12, 2008
  Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
• May 1, 2008
  Abbott, Takeda Conclude TAP Joint Venture
• April 29, 2008
  Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
• March 31, 2008
  New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
• March 19, 2008
  Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
• March 19, 2008
  Takeda Announces New U.S. Leadership
• January 4, 2008
  Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.